✦ LIBER ✦

Initial clinical trial and pharmacokinetics of ThymitaqTM (AG337) by 10-day continuous infusion in patients with advanced solid tumors

✍ Scribed by Patrick J. Creaven; Lakshmi Pendyala; Neal J. Meropol; Neil J. Clendeninn; Ellen Y. Wu; Gregory M. Loewen; April Proefrock; Amanda Johnston; Mary Dixon

Publisher: Springer
Year: 1997
Tongue: English
Weight: 135 KB
Volume: 41
Category: Article
ISSN: 0344-5704
DOI: 10.1007/s002800050724

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Pharmacokinetics and toxicity of 120-hou

Pharmacokinetics and toxicity of 120-hour continuous-infusion hydroxyurea in patients with advanced solid tumors

✍ E. M. Newman; Mary Carroll; Steven A. Akman; Warren Chow; P. Coluzzi; Victor Ham 📂 Article 📅 1996 🏛 Springer 🌐 English ⚖ 118 KB

Phase I clinical trial and pharmacokinet

Phase I clinical trial and pharmacokinetics of weekly ICRF-187 (NSC 169780) infusion in patients with solid tumors

✍ Charles L. Vogel; Elizabeth Gorowski; Enrique Davila; Mario Eisenberger; James K 📂 Article 📅 1987 🏛 Springer US 🌐 English ⚖ 823 KB

ICRF-187 was given to 62 evaluable patients with advanced solid tumors in a Phase I clinical trial. Weekly infusions were given in dosages ranging from 0.85 g/m2 to 7.42 g/m2 for a total of four weeks with a two week rest period between courses. Dose-limiting hematological toxicity was seen in heavi